$AGIO
Agios Pharmaceuticals Inc

2016 Q3 Form 10-Q Financial Statement

#000119312516675231 Filed on August 08, 2016

View on sec.gov

Income Statement

Concept 2016 Q3 2016 Q2 2015 Q2
Revenue $8.985M $6.978M $13.22M
YoY Change 63.96% -47.21% 57.16%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $11.85M $12.64M $8.930M
YoY Change 19.34% 41.55% 114.15%
% of Gross Profit
Research & Development $60.64M $50.80M $36.42M
YoY Change 68.32% 39.48% 61.34%
% of Gross Profit
Depreciation & Amortization $1.400M $1.400M $800.0K
YoY Change 40.0% 75.0% 100.0%
% of Gross Profit
Operating Expenses $72.50M $63.45M $45.35M
YoY Change 57.76% 39.9% 69.6%
Operating Profit -$63.51M -$56.47M -$32.13M
YoY Change 56.92% 75.74% 75.3%
Interest Expense $680.0K $520.0K $240.0K
YoY Change 209.09% 116.67% 700.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$62.83M -$55.95M -$31.90M
YoY Change 56.07% 75.39% 74.36%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$62.83M -$55.95M -$31.90M
YoY Change 56.08% 75.42% 74.34%
Net Earnings / Revenue -699.32% -801.85% -241.3%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.630M -$1.474M -$854.5K
COMMON SHARES
Basic Shares Outstanding 38.05M shares 37.92M shares 37.30M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q3 2016 Q2 2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $579.1M $465.4M $369.8M
YoY Change 64.35% 25.85% 55.06%
Cash & Equivalents $285.5M $234.0M $72.53M
Short-Term Investments $293.6M $231.3M $297.3M
Other Short-Term Assets $10.30M $8.900M $4.600M
YoY Change 43.06% 93.48% -30.3%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $600.9M $484.2M $390.2M
YoY Change 61.69% 24.09% 59.14%
LONG-TERM ASSETS
Property, Plant & Equipment $26.26M $25.13M $19.33M
YoY Change 24.3% 30.04% 502.12%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $43.50M $46.90M $64.20M
YoY Change -21.76% -26.95% 184.07%
Other Assets $1.339M $1.382M $660.0K
YoY Change 97.49% 109.39% 45.05%
Total Long-Term Assets $71.10M $73.44M $84.23M
YoY Change -8.17% -12.81% 213.51%
TOTAL ASSETS
Total Short-Term Assets $600.9M $484.2M $390.2M
Total Long-Term Assets $71.10M $73.44M $84.23M
Total Assets $672.0M $557.6M $474.4M
YoY Change 49.65% 17.54% 74.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $15.42M $18.45M $8.914M
YoY Change 71.93% 106.96% 65.44%
Accrued Expenses $22.81M $14.41M $11.58M
YoY Change 42.68% 24.43% 112.32%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $78.00M $67.26M $45.20M
YoY Change 56.77% 48.82% 1.25%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $192.6M $201.3M $25.00M
YoY Change 712.66% 705.2% 1249900.0%
Total Long-Term Liabilities $192.6M $201.3M $25.00M
YoY Change 712.66% 705.2% 1249900.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $78.00M $67.26M $45.20M
Total Long-Term Liabilities $192.6M $201.3M $25.00M
Total Liabilities $270.6M $268.5M $70.20M
YoY Change 268.66% 282.48% 57.26%
SHAREHOLDERS EQUITY
Retained Earnings -$426.7M -$363.8M -$203.8M
YoY Change 74.82% 78.52% 41.54%
Common Stock $828.1M $652.6M $607.7M
YoY Change 33.67% 7.38% 76.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $401.4M $289.1M $404.2M
YoY Change
Total Liabilities & Shareholders Equity $672.0M $557.6M $474.4M
YoY Change 49.65% 17.54% 74.39%

Cashflow Statement

Concept 2016 Q3 2016 Q2 2015 Q2
OPERATING ACTIVITIES
Net Income -$62.83M -$55.95M -$31.90M
YoY Change 56.08% 75.42% 74.34%
Depreciation, Depletion And Amortization $1.400M $1.400M $800.0K
YoY Change 40.0% 75.0% 100.0%
Cash From Operating Activities -$49.00M $157.8M $4.000M
YoY Change 97.58% 3845.0% -463.64%
INVESTING ACTIVITIES
Capital Expenditures -$3.400M -$2.800M -$10.90M
YoY Change 3.03% -74.31% 10800.0%
Acquisitions
YoY Change
Other Investing Activities -$59.30M $38.50M $43.10M
YoY Change -277.54% -10.67% -332.97%
Cash From Investing Activities -$62.70M $35.70M $32.20M
YoY Change -307.62% 10.87% -273.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 163.2M 1.500M 1.100M
YoY Change 7318.18% 36.36% -98.84%
NET CHANGE
Cash From Operating Activities -49.00M 157.8M 4.000M
Cash From Investing Activities -62.70M 35.70M 32.20M
Cash From Financing Activities 163.2M 1.500M 1.100M
Net Change In Cash 51.50M 195.0M 37.30M
YoY Change 577.63% 422.79% -50.53%
FREE CASH FLOW
Cash From Operating Activities -$49.00M $157.8M $4.000M
Capital Expenditures -$3.400M -$2.800M -$10.90M
Free Cash Flow -$45.60M $160.6M $14.90M
YoY Change 112.09% 977.85% -1590.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
38046368 shares
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
72533000
CY2015Q2 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2015Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2015Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2015Q2 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2016Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6352000
CY2016Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
225564000
CY2016Q2 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
46926000
CY2016Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q2 us-gaap Contracts Receivable Claims And Uncertain Amounts
ContractsReceivableClaimsAndUncertainAmounts
7900000
CY2016Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38029510 shares
CY2016Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38029510 shares
CY2016Q2 us-gaap Assets
Assets
557601000
CY2016Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
17719000
CY2016Q2 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
2933000
CY2016Q2 us-gaap Assets Current
AssetsCurrent
484159000
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2016Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
652574000
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
234048000
CY2016Q2 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2016Q2 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
2014000
CY2016Q2 us-gaap Common Stock Value
CommonStockValue
38000
CY2016Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
183540000
CY2016Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
0
CY2016Q2 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
13 Securities
CY2016Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
18448000
CY2016Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
31469000
CY2016Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1641000
CY2016Q2 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
297000
CY2016Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
231321000
CY2016Q2 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
7853000
CY2016Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2016Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2016Q2 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2016Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
503811000
CY2016Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14414000
CY2016Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
20300000
CY2016Q2 us-gaap Liabilities Current
LiabilitiesCurrent
67264000
CY2016Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
207000
CY2016Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1382000
CY2016Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
73370000
CY2016Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25134000
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
30.04
CY2016Q2 us-gaap Stockholders Equity
StockholdersEquity
289078000
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
45.85
CY2016Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
67811000
CY2016Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
58983000
CY2016Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2016Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
557601000
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2452292 shares
CY2016Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2016Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-363831000
CY2016Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8923000
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5037783 shares
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
46.38
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5383189 shares
CY2016Q2 agio Accrued Contracted Research And Development Costs Current
AccruedContractedResearchAndDevelopmentCostsCurrent
6214000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14031000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7005000
CY2015Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
59332000
CY2015Q4 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
58905000
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Contracts Receivable Claims And Uncertain Amounts
ContractsReceivableClaimsAndUncertainAmounts
8200000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37696502 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37696502 shares
CY2015Q4 us-gaap Assets
Assets
420065000
CY2015Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
17360000
CY2015Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
2479000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
337329000
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
630078000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
71764000
CY2015Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
3374000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
38000
CY2015Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
4699000
CY2015Q4 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
74 Securities
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
14748000
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
19665000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
228000
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-318000
CY2015Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
245238000
CY2015Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
8225000
CY2015Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
363475000
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15996000
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
207400000
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
420065000
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
52888000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1314000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
611000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
153573000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23220000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
345118000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
44.45
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-284680000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8728000
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4618697 shares
CY2015Q4 agio Accrued Contracted Research And Development Costs Current
AccruedContractedResearchAndDevelopmentCostsCurrent
7449000
CY2015Q2 agio Revenue Recognized On Extended Agreement
RevenueRecognizedOnExtendedAgreement
700000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-319000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4719587 shares
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
58502000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.99
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13237000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1531000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15883000
us-gaap Depreciation
Depreciation
1150000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36575000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
3841000
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-13689000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
198078000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2558000
us-gaap Operating Expenses
OperatingExpenses
84749000
us-gaap Net Income Loss
NetIncomeLoss
-36854000
us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
3982000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
77194000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1210000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-125000
us-gaap Operating Income Loss
OperatingIncomeLoss
-37328000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
106205000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2913000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
279000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-6414000
us-gaap Investment Income Interest
InvestmentIncomeInterest
474000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-21605000
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
2948000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
14679000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
68866000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3120000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7002 pure
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
207000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0171 pure
us-gaap Share Based Compensation
ShareBasedCompensation
13237000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y11D
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37272300 shares
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
47421000
agio Collaboration Revenue
CollaborationRevenue
47400000
agio Reimbursement Of Research And Development Related Party Cost
ReimbursementOfResearchAndDevelopmentRelatedPartyCost
8912000
agio Increase Decrease In Research And Development Expense
IncreaseDecreaseInResearchAndDevelopmentExpense
-8900000
agio Proceeds From Stock Options Exercised In Other Current Assets
ProceedsFromStockOptionsExercisedInOtherCurrentAssets
3000
agio Vesting Of Restricted Stock Value Increase Decrease
VestingOfRestrictedStockValueIncreaseDecrease
-4000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-330000
dei Entity Registrant Name
EntityRegistrantName
AGIOS PHARMACEUTICALS INC
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5465406 shares
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001439222
dei Document Period End Date
DocumentPeriodEndDate
2016-06-30
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
162284000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.09
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20103000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1360000
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23481000
us-gaap Depreciation
Depreciation
2550000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-78536000
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-813000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
252468000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-833000
us-gaap Operating Expenses
OperatingExpenses
118323000
us-gaap Net Income Loss
NetIncomeLoss
-79151000
us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
-372000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
20912000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3755000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1129000
us-gaap Operating Income Loss
OperatingIncomeLoss
-80064000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
226289000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2557000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
615000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
190645000
us-gaap Investment Income Interest
InvestmentIncomeInterest
913000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
138815000
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-1360000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5267000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
313183 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M17D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
42.61
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y3M4D
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
73.33
dei Trading Symbol
TradingSymbol
AGIO
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.36
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
94842000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2557000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7172 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1155940 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0141 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
78265 shares
us-gaap Share Based Compensation
ShareBasedCompensation
20103000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y15D
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37910233 shares
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
38259000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y7M6D
agio Collaboration Revenue
CollaborationRevenue
13300000
agio Reimbursement Of Research And Development Related Party Cost
ReimbursementOfResearchAndDevelopmentRelatedPartyCost
14716000
agio Available For Sale Securities Non Current Minimum Liquidating Period
AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod
P12M
agio Increase Decrease In Research And Development Expense
IncreaseDecreaseInResearchAndDevelopmentExpense
-14700000
agio Proceeds From Stock Options Exercised In Other Current Assets
ProceedsFromStockOptionsExercisedInOtherCurrentAssets
23000
CY2014Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
6000000
CY2014Q1 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
1500000
CY2014 agio Initial Agreement Period
InitialAgreementPeriod
P5Y
CY2014 agio Research Collaborative Arrangement Expiration Period
ResearchCollaborativeArrangementExpirationPeriod
2016-04
CY2014 agio Extended Agreement Period
ExtendedAgreementPeriod
P6Y
CY2014 agio Receipt Due To Agreement Amendment
ReceiptDueToAgreementAmendment
20000000
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y5M27D
CY2015 agio Available For Sale Securities Non Current Minimum Liquidating Period
AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod
P12M
CY2015Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4719587 shares
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.85
CY2015Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8177000
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8929000
CY2015Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-31866000
CY2015Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
236000
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
45352000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-31897000
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-32133000
CY2015Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
31000
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36423000
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6893 pure
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0171 pure
CY2015Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M17D
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37329220 shares
CY2015Q2 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
13219000
CY2015Q2 agio Collaboration Revenue
CollaborationRevenue
13200000
CY2015Q2 agio Reimbursement Of Research And Development Related Party Cost
ReimbursementOfResearchAndDevelopmentRelatedPartyCost
4546000
CY2015Q2 agio Increase Decrease In Research And Development Expense
IncreaseDecreaseInResearchAndDevelopmentExpense
-4500000
CY2016Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5465406 shares
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.47
CY2016Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10996000
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12644000
CY2016Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-55745000
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
63448000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-55953000
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-56470000
CY2016Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
208000
CY2016Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
517000
CY2016Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
50804000
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7253 pure
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0138 pure
CY2016Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M21D
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37956383 shares
CY2016Q2 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
6978000
CY2016Q2 agio Collaboration Revenue
CollaborationRevenue
7000000
CY2016Q2 agio Reimbursement Of Research And Development Related Party Cost
ReimbursementOfResearchAndDevelopmentRelatedPartyCost
5922000
CY2016Q2 agio Increase Decrease In Research And Development Expense
IncreaseDecreaseInResearchAndDevelopmentExpense
-5900000

Files In Submission

Name View Source Status
0001193125-16-675231-index-headers.html Edgar Link pending
0001193125-16-675231-index.html Edgar Link pending
0001193125-16-675231.txt Edgar Link pending
0001193125-16-675231-xbrl.zip Edgar Link pending
agio-20160630.xml Edgar Link completed
agio-20160630.xsd Edgar Link pending
agio-20160630_cal.xml Edgar Link unprocessable
agio-20160630_def.xml Edgar Link unprocessable
agio-20160630_lab.xml Edgar Link unprocessable
agio-20160630_pre.xml Edgar Link unprocessable
d85594d10q.htm Edgar Link pending
d85594dex101.htm Edgar Link pending
d85594dex311.htm Edgar Link pending
d85594dex312.htm Edgar Link pending
d85594dex321.htm Edgar Link pending
d85594dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending